Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose iodine-131-MIBG plus myeloablative chemotherapy and HSCT for high-risk neuroblastoma
jRCTs041180030Completed
- Sponsor
- FUJIFILM Toyama Chemical
- Start
- Jan 2018
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Open-label, single-arm trial of Iobenguane I-131 in neuroblastoma, sponsored by FUJIFILM Toyama Chemical. Primary endpoint: Dose-limiting toxicity (DLT). Started Jan 2018; status: completed.
02
Drugs
Iobenguane I-131
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on jRCTs041180030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180030.